dexlansoprazole · Takeda Pharms Usa · NDA 208056
Dexilant Solutab
Earliest generic entry, as listed
10 Mar 2029
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 9241910.
Listed patents · 3 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9241910 | product | 10 Mar 2029 |
| US 8871273 | — | 11 Jul 2028 |
| US 8871273 | product | 11 Jan 2028 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 208056 · 001 · RLD · discontinued | tablet, orally disintegrating, delayed release, oral | 30MG | 10 Mar 2029 |
Expired or delisted (4)
- US 8461187 · — · 17 Jul 2026
- US 9011926 · product · 24 Feb 2026
- US 8461187 · product · 17 Jan 2026
- US 9238029 · product · 17 Jan 2026